Summary
For Year 2026-27, Fredun Pharmaceuticals reports the following shareholding: Total Promoters at 44.17%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 1.06%, Domestic Institutional Investors at 2.83%, and Retail at 51.94%. This breakdown provides a quick snapshot of ownership distribution for Fredun Pharmaceuticals in 2026-27.
Fredun Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Fredun Pharmaceuticals stands at 44.17% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Fredun Pharmaceuticals is 1.06% and 2.83% respectively.
The retail shareholding of the Fredun Pharmaceuticals is 51.94%.
Changes in shareholding patterns of Fredun Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Fredun Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Fredun Pharmaceuticals Associated Pages
- Fredun Pharmaceuticals Share Price
- Fredun Pharmaceuticals Share Price chart
- Fredun Pharmaceuticals Fundamental Analysis
- Fredun Pharmaceuticals Technical Analysis
- Fredun Pharmaceuticals Peer Comparison
- Fredun Pharmaceuticals Share Price History
- Fredun Pharmaceuticals Dividend
- Fredun Pharmaceuticals Board of Directors
